Home > Products > CD64 & EGFR
> Recombinant Anti-CD64 x Anti-EGFR VHH BispecificAntibody (IgG-VHH)
Recombinant Anti-CD64 x Anti-EGFR VHH BispecificAntibody (IgG-VHH) (CAT#: IGVHH-036)
Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (IgG-VHH) is designed to be expressed as a LC and an extended HC with VHH moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, bivalent for each antigen specificity, 2+2 antigen-binding valency. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-EGFR VHH BispecificAntibody (IgG-VHH) (IGVHH-036). Click the button below to contact us or submit your feedback about this product.